Eli Lilly And Company (LLY): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Eli Lilly and Company ( LLY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, Eli Lilly and Company rose $1.40 (2.6%) to $54.96 on heavy volume. Throughout the day, 14,177,301 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,301,100 shares. The stock ranged in a price between $54.73-$56.50 after having opened the day at $56.00 as compared to the previous trading day's close of $53.56. Other companies within the Drugs industry that increased today were: Osiris Therapeutics ( OSIR), up 138.7%, GW Pharmaceuticals PLC ADR ( GWPH), up 16.4%, Prana Biotechnology ( PRAN), up 10.3% and Stemline Therapeutics ( STML), up 9.1%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $61.0 billion and is part of the health care sector. Shares are up 9.9% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Aastrom Biosciences ( ASTM), down 43.4%, Alimera ( ALIM), down 20.7%, Savient Pharmaceuticals ( SVNT), down 14.5% and Zalicus ( ZLCS), down 13.1% , were all laggards within the drugs industry with Celgene Corporation ( CELG) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Here's How Eli Lilly Stock Can Regain Its Footing

Here's How Eli Lilly Stock Can Regain Its Footing

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls